Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 175 of 1048 entries
View as:

HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06217042 Org: User:
Start: 02/05/24 End: 07/30/28 Due: 07/30/29

The First Line Treatment of Fruquintinib Combined With Albumin Paclitaxel and Gemcitabine in Pancreatic Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT05168527 Org: User:
Start: 09/03/21 End: 05/31/24 Due: 05/31/25

Effect of Dexmedetomidine on Bispectral Index and Propofol Requirements During Different Menstrual Cycle

Phase: N/A Priority: Normal
NCT ID: NCT02035930 Org: User:
Start: 11/30/10 End: 11/30/12 Due: 11/30/13

The Efficacy and Safety of Narlumosbart in Combination with Stereotactic Body Radiation Therapy to Improve the Efficacy of First-line Chemotherapy Combined with Immunotherapy in Patients with Bone Metastases from Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06738160 Org: User:
Start: 05/20/25 End: 12/01/28 Due: 12/01/29

NX in Luminal B Breast Cancer Patients After Neoadjuvant Chemotherapy

Phase: N/A Priority: Normal
NCT ID: NCT04307147 Org: User:
Start: 07/03/18 End: 09/01/21 Due: 09/01/22

Resection of the Nerve Plexus on the Right Half of Celiac and SMA Associated With Extended Pancreatoduodenectomy in the Surgical Treatment for Adenocarcinoma of the Head of Pancreas

Phase: N/A Priority: Normal
NCT ID: NCT02514928 Org: User:
Start: 06/30/15 End: 06/30/19 Due: 06/30/20

HAIC Combined With TQB2450 and Anlotinib in Second-line Treatment of Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06475287 Org: User:
Start: 07/20/24 End: 07/31/26 Due: 07/31/27

500mg Fulvestrant Versus Everolimus Plus Exemestane in MBC Patients Refractory to Previous AI

Phase: N/A Priority: Normal
NCT ID: NCT03695341 Org: User:
Start: 05/14/18 End: 05/15/19 Due: 05/15/20

Study of Antivascular Therapy Combined With Chemotherapy Versus Chemotherapy in Adjuvant Therapy of TNBC-BLIS Patients (BCTOP-T-A03)

Phase: N/A Priority: Normal
NCT ID: NCT05909332 Org: User:
Start: 06/20/23 End: 05/30/31 Due: 05/30/32

Fruquintinib in the Treatment of Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT05142631 Org: User:
Start: 11/21/21 End: 08/30/23 Due: 08/30/24

Efficacy and Safety of Pyrotinib in HER2 Positive Gastrointestinal Tumors

Phase: N/A Priority: Normal
NCT ID: NCT04960943 Org: User:
Start: 02/01/20 End: 03/01/23 Due: 03/01/24

Secondary Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy for PARP Inhibitors Resistance Patients

Phase: N/A Priority: Normal
NCT ID: NCT06544460 Org: User:
Start: 08/31/24 End: 12/31/26 Due: 12/31/27

Famitinib in Combination With Camrelizumab and TPC in The First-line Treatment of Immunomodulatory Locally Advanced or Metastatic TNBC.

Phase: N/A Priority: Normal
NCT ID: NCT05760378 Org: User:
Start: 03/17/23 End: 01/01/27 Due: 01/01/28

Weekly Utidelone in HER2-negative Inoperable Locally Advanced or Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05403333 Org: User:
Start: 06/10/22 End: 03/09/25 Due: 03/09/26

MRD-Guided Surveillance in Locally Advanced Mid-Low Rectal Cancer (SURVEILLANCE-III)

Phase: N/A Priority: Normal
NCT ID: NCT06879899 Org: User:
Start: 08/01/25 End: 07/31/29 Due: 07/31/30

Efficacy and Safety Study of Neoadjuvant Chemotherapy for Local Advanced Triple Negative Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT01216124 Org: User:
Start: - End: - Due: -

Dalpicilib-Enhanced Vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06637150 Org: User:
Start: 09/01/24 End: 09/30/30 Due: 09/30/31

Local Therapy for Oligometastatic ESCC Patients Treated With PD-1 Inhibitor

Phase: N/A Priority: Normal
NCT ID: NCT06190782 Org: User:
Start: 09/27/22 End: 09/27/27 Due: 09/27/28

Study on the Safety and Efficacy of Intratumoral Administration of IDOV-SAFETM in the Treatment of Advanced Solid Tumors

Phase: N/A Priority: Normal
NCT ID: NCT06713148 Org: User:
Start: 04/10/25 End: 12/31/27 Due: 12/31/28

Study of S-1 in Combination With Radiotherapy in Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01831531 Org: User:
Start: 03/31/13 End: 10/31/18 Due: 10/31/19

The Combination of Radiotherapy, Chemotherapy and Immunotherapy in High-Risk Localized Soft Tissue Sarcoma

Phase: N/A Priority: Normal
NCT ID: NCT05774275 Org: User:
Start: 08/25/22 End: 08/24/29 Due: 08/24/30

IO Combined With AI as First-line Treatment for Patients With Soft Tissue Sarcoma(TAIS)

Phase: N/A Priority: Normal
NCT ID: NCT06849986 Org: User:
Start: 02/25/25 End: 12/31/29 Due: 12/31/30

Treatment of Cerebral Radiation Necrosis (CRN) With Nerve Growth Factor (NGF)

Phase: N/A Priority: Normal
NCT ID: NCT02032147 Org: User:
Start: 03/31/09 End: 10/31/12 Due: 10/31/13

SBRT for Oligo-metastatic Lesions After Systemic Treatment of Primary Metastatic Nasopharyngeal Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT04351282 Org: User:
Start: 06/01/20 End: 05/31/26 Due: 05/31/27

Evaluation of a Model for the Early Diagnosis of Colorectal Cancer by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNA to the Community Colorectal Cancer Screening Program

Phase: N/A Priority: Normal
NCT ID: NCT05638243 Org: User:
Start: 08/20/22 End: 09/30/25 Due: 09/30/26